Home
Clinical Trials
A Study on the Safety, Reacto...

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

Last Updated: 2024-01-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

516 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-15

Study Completion Date

2026-04-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-generalized modules for membrane antigens (iNTS-GMMA) candidate vaccine against S. Typhimurium and S. Enteritidis with an age de-escalation and dose escalation approach in African population, starting with adults (18-50 years of age), then on children (24-59 months of age) and finally to infants (9 months and 6 weeks of age). Infants are the target for primary vaccination from 6 weeks of age.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants

NCT07286370

Salmonella Infections

NOT_YET_RECRUITING PHASE2

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants

NCT05073003

Diarrhoea

COMPLETED PHASE1

Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™

NCT00678301

Infections, Streptococcal

COMPLETED PHASE3

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614

Infections, Meningococcal

COMPLETED PHASE3

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263

Poliomyelitis Diphtheria Haemophilus Influenzae Type b +3 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be conducted in two stages:

Stage 1: Age De-escalation from Adults to Children and Infants

* Adult participants will receive either iNTS-GMMA Dose C (high) or a control vaccine intramuscularly on Day 1 and Day 57.
* Child participants will receive either Dose B (medium) or Dose C (high) of the candidate vaccine or the control on Day 1 and Day 57.
* Infant participants (9 months of age) will receive either Dose A (low), Dose B (medium), or Dose C (high) of the candidate vaccine or the control on Day 1, Day 85, and Day 169.
* Infant participants (6 weeks of age) will receive either Dose A (low), Dose B (medium), or Dose C (high) of the candidate vaccine or the control on Day 1, Day 85 (Priming phase), and Day 232 (Booster phase).

Stage 2: Dose-finding in Infants of 6 weeks of age

-Infants (6 weeks of age) will receive one of the three dose levels (Dose A \[low\], Dose B \[medium\], or Dose C \[high\]) of the candidate vaccine or the control on Day 1, Day 85 (Priming phase), and Day 232 (Booster phase).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Salmonella Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Data will be collected in an observer-blind manner.

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adults_Dose C Group

Adults 18-50 years of age, part of the safety cohort, randomized to receive 2 doses of the iNTS-GMMA Dose C vaccine at Day 1 and Day 57.

Group Type EXPERIMENTAL

iNTS-GMMA Dose C

Intervention Type BIOLOGICAL

-2 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1 and Day 57 to adults and children in the Adults\_Dose C and Children\_Dose C groups; -3 doses of iNTS-GMMA Dose C vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose C group, and at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants\_6W\_Dose C and Infants\_6W\_Dose C\_2 groups.

Adults_Control Group

Adults 18-50 years of age, part of the safety cohort, randomized to receive 1 dose of the MenACWY vaccine at Day 1 and 1 dose of Placebo at Day 57.

Group Type ACTIVE_COMPARATOR

MenACWY

Intervention Type BIOLOGICAL

-1 dose of MenACWY vaccine administered intramuscularly at Day 1 to adults in the Adults\_Control group; -2 doses of MenACWY vaccine administered intramuscularly at Day 1 and Day 57 to children in the Children\_Control B and Children\_Control C groups, and at Day 1 and Day 85 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups; -3 doses of MenACWY vaccine administered intramuscularly at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase) to infants in the Infants\_6W\_Control A, Infants\_6W\_Control B, Infants\_6W\_Control C and Infants\_6W\_Control\_2 groups. A 4th dose of MenACWY vaccine is administered after the trial ends, to infants in the aforementioned study groups, as per the licensed indication and in private vaccination settings.

Placebo

Intervention Type DRUG

1 dose of Placebo administered intramuscularly at Day 57 to adults in the Adults\_Control group.

Children_Dose B Group

Children 24-59 months of age, part of the safety cohort, randomized to receive 2 doses of the iNTS-GMMA Dose B vaccine at Day 1 and Day 57.

Group Type EXPERIMENTAL

iNTS-GMMA Dose B

Intervention Type BIOLOGICAL

-2 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1 and Day 57 to children in the Children\_Dose B group; -3 doses of iNTS-GMMA Dose B vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose B group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants\_6W\_Dose B and Infants\_6W\_Dose B\_2 groups.

Children_Control B Group

Children 24-59 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 57.

Group Type ACTIVE_COMPARATOR

MenACWY

Intervention Type BIOLOGICAL

Children_Dose C Group

Children 24-59 months of age, part of the safety cohort, randomized to receive 2 doses of the iNTS-GMMA Dose C vaccine at Day 1 and Day 57.

Group Type EXPERIMENTAL

iNTS-GMMA Dose C

Intervention Type BIOLOGICAL

Children_Control C Group

Children 24-59 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 57.

Group Type ACTIVE_COMPARATOR

MenACWY

Intervention Type BIOLOGICAL

Infants_9M_Dose A Group

Infants 9 months of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose A vaccine at Day 1, Day 85 and Day 169. These infants also receive an Expanded Program on Immunization (EPI) vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.

Group Type EXPERIMENTAL

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Measles and Rubella vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants\_9M\_Dose A, Infants\_9M\_Control A, Infants\_9M\_Dose B, Infants\_9M\_Control B, Infants\_9M\_Dose C and Infants\_9M\_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants\_6W\_Dose A, Infants\_6W\_Control A, Infants\_6W\_Dose B, Infants\_6W\_Control B, Infants\_6W\_Dose C and Infants\_6W\_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.

Yellow Fever vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine is administered to study participants, as part of an Expanded Program on Immunization (EPI) vaccination at the local EPI vaccination centers, and not part of the current clinical trial, as follows: - at 28 days after the first study intervention administration (occurring at Day 1) to infants in the Infants\_9M\_Dose A, Infants\_9M\_Control A, Infants\_9M\_Dose B, Infants\_9M\_Control B, Infants\_9M\_Dose C and Infants\_9M\_Control C groups. - at 28 days after the third study intervention administration (occurring at Day 232) to infants in Infants\_6W\_Dose A, Infants\_6W\_Control A, Infants\_6W\_Dose B, Infants\_6W\_Control B, Infants\_6W\_Dose C and Infants\_6W\_Control C groups. - at Day 232, concomitantly during the last study intervention administration to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.

iNTS-GMMA Dose A

Intervention Type BIOLOGICAL

3 doses of iNTS-GMMA Dose A vaccine administered intramuscularly, at Day 1, Day 85 and Day 169 to infants in the Infants\_9M\_Dose A group, and at Day 1, Day 57 (during the Priming phase) and Day at 232 (during the Booster phase) to infants in the Infants\_6W\_Dose A and Infants\_6W\_Dose A\_2 groups.

Infants_9M_Control A Group

Infants 9 months of age, part of the safety cohort, randomized to receive 2 doses of the MenACWY vaccine at Day 1 and Day 85 and 1 dose of the DTPaHBV-IPV+Hib vaccine at Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.

Group Type ACTIVE_COMPARATOR

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

MenACWY

Intervention Type BIOLOGICAL

DTPa-HBV-IPV+Hib

Intervention Type COMBINATION_PRODUCT

1 dose of DTPa-HBV-IPV+Hib vaccine administered intramuscularly at Day 169 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups.

Infants_9M_Dose B Group

Infants 9 months of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose B vaccine at Day 1, Day 85 and Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.

Group Type EXPERIMENTAL

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

iNTS-GMMA Dose B

Intervention Type BIOLOGICAL

Infants_9M_Control B Group

Group Type ACTIVE_COMPARATOR

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

MenACWY

Intervention Type BIOLOGICAL

DTPa-HBV-IPV+Hib

Intervention Type COMBINATION_PRODUCT

1 dose of DTPa-HBV-IPV+Hib vaccine administered intramuscularly at Day 169 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups.

Infants_9M_Dose C Group

Infants 9 months of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose C vaccine at Day 1, Day 85 and Day 169. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the first study intervention administration occurring at Day 1, at the local EPI vaccination centers, and not part of the current clinical trial.

Group Type EXPERIMENTAL

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

iNTS-GMMA Dose C

Intervention Type BIOLOGICAL

Infants_9M_Control C Group

Group Type ACTIVE_COMPARATOR

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

MenACWY

Intervention Type BIOLOGICAL

DTPa-HBV-IPV+Hib

Intervention Type COMBINATION_PRODUCT

1 dose of DTPa-HBV-IPV+Hib vaccine administered intramuscularly at Day 169 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups.

Infants_6W_Dose A Group

Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose A vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.

Group Type EXPERIMENTAL

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

iNTS-GMMA Dose A

Intervention Type BIOLOGICAL

Infants_6W_Control A Group

Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the MenACWY vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). To allow completion of the vaccination schedule a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.

Group Type ACTIVE_COMPARATOR

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

MenACWY

Intervention Type BIOLOGICAL

Infants_6W_Dose B Group

Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose B vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.

Group Type EXPERIMENTAL

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

iNTS-GMMA Dose B

Intervention Type BIOLOGICAL

Infants_6W_Control B Group

Group Type ACTIVE_COMPARATOR

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

MenACWY

Intervention Type BIOLOGICAL

Infants_6W_Dose C Group

Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose C vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.

Group Type EXPERIMENTAL

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

iNTS-GMMA Dose C

Intervention Type BIOLOGICAL

Infants_6W_Control C Group

Group Type ACTIVE_COMPARATOR

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

MenACWY

Intervention Type BIOLOGICAL

Infants_6W_Dose A_2 Group

Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the iNTS-GMMA Dose A vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last iNTS-GMMA administration at Day 232, and the pentavalent vaccine (DTPwHepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.

Group Type EXPERIMENTAL

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

Pentavalent vaccine

Intervention Type BIOLOGICAL

Pentavalent vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.

Pneumococcal vaccine

Intervention Type BIOLOGICAL

Pneumococcal vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.

Inactivated polio vaccine

Intervention Type BIOLOGICAL

Inactivated polio vaccine is administered, as part of an Expanded Program on Immunization (EPI) vaccination, at the local EPI vaccination centers, and not part of the current clinical trial, at 6, 10 and 14 weeks of age to infants in Infants\_6W\_Dose A\_2, Infants\_6W\_Dose B\_2, Infants\_6W\_Dose C\_2 and Infants\_6W\_Control\_2 groups.

iNTS-GMMA Dose A

Intervention Type BIOLOGICAL

Infants_6W_Dose B_2 Group

Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the iNTS-GMMA Dose B vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last iNTS-GMMA administration at Day 232, and the pentavalent vaccine (DTPwHepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.

Group Type EXPERIMENTAL

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

Pentavalent vaccine

Intervention Type BIOLOGICAL

Pneumococcal vaccine

Intervention Type BIOLOGICAL

Inactivated polio vaccine

Intervention Type BIOLOGICAL

iNTS-GMMA Dose B

Intervention Type BIOLOGICAL

Infants_6W_Dose C_2 Group

Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the iNTS-GMMA Dose C vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last iNTS-GMMA administration at Day 232, and the pentavalent vaccine (DTPwHepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.

Group Type EXPERIMENTAL

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

Pentavalent vaccine

Intervention Type BIOLOGICAL

Pneumococcal vaccine

Intervention Type BIOLOGICAL

Inactivated polio vaccine

Intervention Type BIOLOGICAL

iNTS-GMMA Dose C

Intervention Type BIOLOGICAL

Infants_6W_Control_2 Group

Infants 6 weeks of age, part of the dose-finding cohort, randomized to receive 3 doses of the MenACWY vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). To allow completion of the vaccination schedule a fourth dose of the MenACWY vaccine is administered after the trial ends, as per the licensed indication and in private vaccination settings. These infants also receive an EPI vaccination with the following vaccines: Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine administered concomitantly during the last study intervention administration at Day 232, and the pentavalent vaccine (DTPw-HepB-Hib), the Pneumococcal conjugate vaccine, and the inactivated polio vaccine administered at the same time, at 6, 10 and 14 weeks of age, at the local EPI vaccination centers, and not part of the current clinical trial.

Group Type ACTIVE_COMPARATOR

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

Pentavalent vaccine

Intervention Type BIOLOGICAL

Pneumococcal vaccine

Intervention Type BIOLOGICAL

Inactivated polio vaccine

Intervention Type BIOLOGICAL

MenACWY

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Measles and Rubella vaccine

Intervention Type BIOLOGICAL

Yellow Fever vaccine

Intervention Type BIOLOGICAL

Pentavalent vaccine

Intervention Type BIOLOGICAL

Pneumococcal vaccine

Intervention Type BIOLOGICAL

Inactivated polio vaccine

Intervention Type BIOLOGICAL

iNTS-GMMA Dose C

Intervention Type BIOLOGICAL

iNTS-GMMA Dose B

Intervention Type BIOLOGICAL

iNTS-GMMA Dose A

Intervention Type BIOLOGICAL

MenACWY

Intervention Type BIOLOGICAL

DTPa-HBV-IPV+Hib

1 dose of DTPa-HBV-IPV+Hib vaccine administered intramuscularly at Day 169 to infants in the Infants\_9M\_Control A, Infants\_9M\_Control B and Infants\_9M\_Control C groups.

Intervention Type COMBINATION_PRODUCT

Placebo

1 dose of Placebo administered intramuscularly at Day 57 to adults in the Adults\_Control group.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MR-VAC DTPw-HepB-Hib Menveo Infanrix hexa

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All participants (adults, children, infants at 9 months of age and infants at 6 weeks of age) will be enrolled in the clinical site in Ghana and must satisfy ALL the following criteria at study entry:

* Participants and/or participants' parent(s)/Legally Acceptable Representative(s) (LAR), who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits).
* Written or witnessed/thumb printed informed consent obtained from the participant/parent(s)/LAR(s) of the participant prior to performance of any study-specific procedure.
* Healthy participants as established by medical history, clinical examination, and laboratory investigations.
* Participants satisfying screening requirements.
* Participants negative for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.

Adult participants must satisfy ALL the following criteria at study entry:

* A male or female between and including 18 and 50 years of age at the time of the first study intervention administration.
* Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.
* Female participants of childbearing potential may be enrolled in the study if the participant:

has practiced adequate contraception for 1 month prior to study intervention administration, and:

* has a negative pregnancy test on the day of study intervention administration, and
* has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.

The Ghana card will be used as source document to verify the ages for the adults.

Child participants must satisfy ALL the following criteria at study entry:

* A male or female between and including 24 and 59 months of age at the time of the first study intervention administration.
* Previously completed routine childhood vaccinations to the best knowledge of the participant's parent(s)/LAR's.
* Born after a gestation period of ≥37 weeks.

Infant participants must satisfy ALL the following criteria at study entry:

* A male or female 6 weeks or 9 months of age at the time of the first study intervention administration.
* Born after a gestation period of ≥37 weeks.
* Born to a mother seronegative for HIV, hepatitis B virus and hepatitis C virus.

The Road to Health Chart will be used as source document to confirm the ages for the children and infants.

Exclusion Criteria

Medical conditions

* Known exposure to S. Typhimurium or S. Enteritidis during the period starting at birth for infants and children, and at 3 years for adults, as documented by patient records
* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.
* Hypersensitivity, including allergy, to medicinal products or medical equipment whose use is foreseen in this study.
* Progressive, unstable, or uncontrolled clinical conditions.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
* Major congenital defects, as assessed by the investigator.
* Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests.
* Acute disease and/or fever at the time of enrollment (fever is defined as temperature ≥ 38.0°C).
* Recurrent history or uncontrolled neurological disorders or seizures.
* Any clinically significant hematological and/or biochemical laboratory abnormality.
* Undernutrition defined as WHO Z-score less than -2 SD.
* Malaria infection defined as the presence of asexual parasites in the blood.
* Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
* Any behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the study.
* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.

Prior/Concomitant therapy

* History of receiving any investigational iNTS or GMMA vaccines in the participant's life.
* Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days before the first dose of study interventions, or their planned use during the study period.
* Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 14 days before each dose and ending 28 days after the last dose of study interventions administration, with the exception of flu vaccines and vaccines administered as part of a public health vaccination campaign.
* A vaccine not foreseen by the study protocol administered during the period starting at 14 days before the first dose and ending 14 days after the last dose of study interventions administration for live vaccines or 7 days in case of inactivated vaccines\*, with the exception of flu vaccines or COVID-19 vaccine which may be considered on a case-by-case basis.

* If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is organized by public health authorities outside the routine immunization program, the time period described above can be reduced if, provided it is used according to the local governmental recommendations and Sponsor is notified.

* Administration of long-acting immune-modifying drugs at any time during the study period.
* Administration of immunoglobulins and/or any blood products or plasma derivatives from birth (for infant 6 weeks of age) or during the period starting 3 months before the administration of the first dose of study intervention(s) or planned administration during the study period.
* Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose(s) up to the end of the study. For corticosteroids, this will mean prednisone equivalent greater than or equal to (\>=) 20 mg/day for adult participants/ \>= 0.5 mg/kg/day with maximum of 20 mg/day for pediatric participants (infants and children). Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (vaccine, drug and device).

Other exclusions

* Pregnant or lactating female.
* Female planning to become pregnant or planning to discontinue contraceptive precautions.
* History of/current chronic alcohol consumption and/or drug abuse. This will be decided at the discretion of the investigator.
* Any study personnel or their immediate dependents, family, or household members.
* Child in care.

Minimum Eligible Age

6 Weeks

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes